PTPI — Petros Pharmaceuticals Income Statement
0.000.00%
- $13.33m
- $16.86m
- $5.11m
Annual income statement for Petros Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9.56 | 7.81 | 5.99 | 5.82 | 5.11 |
Cost of Revenue | |||||
Gross Profit | 5.51 | 6.21 | 3.7 | 4.19 | 3.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 26.8 | 25.9 | 25.9 | 19.4 | 22.8 |
Operating Profit | -17.3 | -18 | -19.9 | -13.6 | -17.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22 | -8.99 | -20 | -8.16 | -14.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -20.6 | -8.99 | -20 | -8.16 | -14.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -20.6 | -8.99 | -20 | -8.16 | -14.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -20.6 | -8.99 | -20 | -13.8 | -26.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -21.2 | -8.25 | -7.71 | -6.35 | -2.42 |
Dividends per Share |